Last reviewed · How we verify
SOX plus PD-1 inhibitor
SOX chemotherapy combined with a PD-1 inhibitor uses cytotoxic drugs to kill cancer cells while simultaneously blocking PD-1 to enhance anti-tumor immune responses.
SOX chemotherapy combined with a PD-1 inhibitor uses cytotoxic drugs to kill cancer cells while simultaneously blocking PD-1 to enhance anti-tumor immune responses. Used for Gastric cancer or gastroesophageal junction cancer (likely primary indication based on SOX use).
At a glance
| Generic name | SOX plus PD-1 inhibitor |
|---|---|
| Sponsor | Liaoning Cancer Hospital & Institute |
| Drug class | Chemotherapy + PD-1 inhibitor combination |
| Target | PD-1 (programmed death receptor 1); S-1 (thymidylate synthase/5-FU metabolism); oxaliplatin (DNA cross-linking) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
SOX is a chemotherapy regimen (S-1 and oxaliplatin) that directly damages cancer cell DNA and triggers cell death. The PD-1 inhibitor removes immune checkpoint inhibition, allowing T cells to recognize and attack cancer cells more effectively. This combination leverages both direct cytotoxicity and immune activation for enhanced anti-tumor efficacy.
Approved indications
- Gastric cancer or gastroesophageal junction cancer (likely primary indication based on SOX use)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea/vomiting
- Diarrhea
- Immune-related adverse events (fatigue, rash, hepatotoxicity)
Key clinical trials
- Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)
- A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer (PHASE2)
- Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach (PHASE2)
- Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma (PHASE1, PHASE2)
- Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer (PHASE2, PHASE3)
- Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology (PHASE4)
- Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer (PHASE2)
- Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SOX plus PD-1 inhibitor CI brief — competitive landscape report
- SOX plus PD-1 inhibitor updates RSS · CI watch RSS
- Liaoning Cancer Hospital & Institute portfolio CI